Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
FDA Confirms Eligibility of XORLO™ for Accelerated Approval
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada
Canada needs to invest now to address antimicrobial resistance
Alberta becomes the first province to list Trodelvy for triple-negative breast cancer
